Current pharmacotherapy of central precocious puberty by GnRH analogs: certainties and uncertainties

Bibliography

• Fuqua JS. Treatment and outcomes of precocious puberty: an update. J Clin Endocrinol Metab 2013;98:2198-207
   PubMed Web of Science ®Google Scholar
• Sørensen K, Mouritsen A, Aksglaede L, et al. Recent secular trends in pubertal timing: implications for evaluation and diagnosis of precocious puberty. Horm Res Paediatr 2012;77:137-45
   PubMed Web of Science ®Google Scholar
• Tena-Sempere M. Deciphering puberty: novel partners, novel mechanisms. Eur J Endocrinol 2012;167:733-47
   PubMed Web of Science ®Google Scholar
• Grumbach MM, Styne DM. Puberty: Ontogeny, neuroendocrinology, physiology, and disorders. In: Wilson JD, et al. editors. Williams textbook of endocrinology. 9th edition. W.B. Saunders, Philadelphia; 1998. p. 1509-625
   Google Scholar
• Thamdrup E. Precocious sexual development, a clinical study of 100 children. Munksgaard, Kopenhagen; 1961. p. 104-5
   Google Scholar
• Bridges NA, Christopher JA, Hindmarsh PC, et al. Sexual precocity: sex incidence and aetiology. Arch Dis Child 1994;70:116-18
   PubMed Web of Science ®Google Scholar
• Cisternino M, Arrigo T, Pasquino AM, et al. Etiology and age incidence of precocious puberty in girls: a multicentric study. J Pediatr Endocrinol Metab 2000;13(Suppl 1):695-701
   PubMedGoogle Scholar
• De Sanctis V, Corrias A, Rizzo V, et al. Etiology of central precocious puberty in males: the results of the Italian Study Group for Physiopathology of Puberty. J Pediatr Endocrinol Metab 2000;13(Suppl 1):687-93
   PubMedGoogle Scholar
• Chemaitilly W, Trivin C, Adan L, et al. Central precocious puberty: clinical and laboratory features. Clin Endocrinol (Oxf) 2001;54:289-94
   PubMed Web of Science ®Google Scholar
• Oerter-Klein K, Barnes KM, Jones JV, et al. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab 2001;86:4711-16
   PubMedGoogle Scholar
• Lee PA, Neely EK, Fuqua J, et al. Efficacy of leuprolide acetate 1-month depot for central precocious puberty (cpp): growth outcomes during a prospective, longitudinal study. Int J Pediatr Endocrinol 2011;2011:7
   PubMedGoogle Scholar
• Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009;123:e752-62
   PubMed Web of Science ®Google Scholar
• Partsch CJ, Sippell WG. Treatment of central precocious puberty. Best Pract Res Clin Endocrinol Metab 2002;16:165-89
   PubMed Web of Science ®Google Scholar
• Lahlou N, Carel JC, Chaussain JL, Roger M. Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab 2000;13(Suppl 1):723-37
   PubMedGoogle Scholar
• Boepple PA, Mansfield MJ, Wierman ME, et al. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty. Endocr Rev 1986;7:24-33
   PubMed Web of Science ®Google Scholar
• Bouchot O, Soret SY, Jacqmin D, et al. Three-month sustained-release form of triptorelin in patients with advanced prostatic adenocarcinoma: results of an open pharmacodynamic and pharmacokinetic multicenter study. Horm Res 1998;50:89-93
   PubMedGoogle Scholar
• Okada H, Doken Y, Ogawa Y, Toguchi H. Sustained suppression of the pituitary-gondadal axis by leuprorelin three-month depot microspheres in rats and dogs. Pharm Res 1994;11:1199-203
   PubMedGoogle Scholar
• Dineen MK, Tierney DS, Kuzma P, et al. An evaluation of the pharmacokinetics and pharmacodynamics of the histrelin implant for the palliative treatment of prostate cancer. J Clin Pharmacol 2005;45:1245-9
   PubMed Web of Science ®Google Scholar
• Hirsch HJ, Gillis D, Strich D, et al. The histrelin implant: a novel treatment for central precocious puberty. Pediatrics 2005;116:e798-802
   PubMed Web of Science ®Google Scholar
• Lewis KA, Eugster EA. Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty. Drug Des Dev Ther 2009;3:1-5
   PubMed Web of Science ®Google Scholar
• Rahhal S, Clarke WL, Kletter GB, et al. Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty. Int J Pediatr Endocrinol 2009;2009:812517
   PubMedGoogle Scholar
• Bertelloni S, Mul D. Treatment of central precocious puberty by GnRH analogs: long-term outcome in men. Asian J Androl 2008;10:525-34
   PubMed Web of Science ®Google Scholar
• Paterson WF, McNeill E, Reid S, et al. Efficacy of Zoladex LA (goserelin) in the treatment of girls with central precocious or early puberty. Arch Dis Child 1998;79:323-7
   PubMedGoogle Scholar
• Paterson WF, McNeill E, Young D, et al. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty. Clin Endocrinol (Oxf) 2004;61:626-34
   PubMedGoogle Scholar
• Mul D, Oostdijk W, Otten BJ, et al. Final height after gonadotrophin releasing hormone agonist treatment for central precocious puberty: the Dutch experience. J Pediatr Endocrinol Metab 2000;13(Suppl 1):765-72
   PubMedGoogle Scholar
• Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab 1999;84:4583-90
   PubMed Web of Science ®Google Scholar
• Carel J-C, Roger M, Ispas S, et al. Final height after long-term treatment with Triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. J Clin Endocrinol Metab 1999;84:1973-8
   PubMed Web of Science ®Google Scholar
• Pasquino AM, Pucarelli I, Accardo F, et al. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab 2008;93:190-5
   PubMed Web of Science ®Google Scholar
• Magiakou MA, Manousaki D, Papadaki M, et al. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. J Clin Endocrinol Metab 2010;95:109-17
   PubMed Web of Science ®Google Scholar
• Lazar L, Padoa A, Phillip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab 2007;92:3483-9
   PubMed Web of Science ®Google Scholar
• Adan L, Chemaitilly W, Trivin C, et al. Factors predicting adult height in girls with central precocious puberty: implications for treatment. Clin Endocrinol 2002;56:297-302
   PubMed Web of Science ®Google Scholar
• Arrigo T, Cisternino M, Galluzzi F, et al. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. Eur J Endocrinol 1999;141:140-4
   PubMed Web of Science ®Google Scholar
• Adan L, Chemaitilly W, Trivin C, et al. Factors predicting adult height in girls with idiopathic central precocious puberty: implications for treatment. Clin Endocrinol (Oxf) 2002;56:297-302
   PubMed Web of Science ®Google Scholar
• Chiocca E, Dati E, Baroncelli GI, et al. Body mass index and body composition in adolescents treated with gonadotropin-releasing hormone analogue triptorelin depot for central precocious puberty: data at near final height. Neuroendocrinology 2009;89:441-7
   PubMedGoogle Scholar
• Mul D, Bertelloni S, Carel JC, et al. Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty. Horm Res 2002;58:1-7
   PubMedGoogle Scholar
• Carel JC, Lahlou N, Guazzarotti L, et al. Treatment of central precocious puberty with depot leuprorelin. French Leuprorelin Trial Group. Eur J Endocrinol 1995;132:699-704
   PubMedGoogle Scholar
• Brito VN, Latronico AC, Cukier P, et al. Factors determining normal adult height in girls with gonadotropin-dependent precocious puberty treated with depot gonadotropin-releasing hormone analogs. J Clin Endocrinol Metab 2008;93:2662-9
   PubMedGoogle Scholar
• Tanaka T, Niimi H, Matsuo N, et al. Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty. J Clin Endocrinol Metab 2005;90:1371-6
   PubMed Web of Science ®Google Scholar
• Jaruratanasirikul S, Thaiwong M. Outcome of gonadotropin-releasing analog treatment for children with central precocious puberty: 15-year experience in southern Thailand. J Pediatr Endocr Met 2011;24:519-23; leuprolide
   PubMedGoogle Scholar
• Cook JS, Doty KL, Conn PM, et al. Assessment of depot leuprolide acetate dose-adequacy for central precocious puberty. J Clin Endocrinol Metab 1992;74:1206-9
   PubMed Web of Science ®Google Scholar
• Partsch CJ, Hümmelink R, Peter M, et al. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group. Horm Res 1993;39:111-17
   PubMedGoogle Scholar
• Massart F, Federico G, Harrell JC, et al. Growth outcome during GnRH agonist treatments for slowly progressive central precocious puberty. Neuroendocrinology 2009;90:307-14
   PubMed Web of Science ®Google Scholar
• Lanes R, Soros A, Jakubowicz S. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin- suppressive effect and final height obtained with two different analogs. J Pediatr Endocrinol Metab 2004;17:759-66
   PubMed Web of Science ®Google Scholar
• Schroeter M, Baus I, Sippell WG, et al. Long-term suppression of pituitary-gonadal function with three-month depot of leuprorelin acetate in a girl with central precocious puberty. Horm Res 2002;58:292-6
   PubMedGoogle Scholar
• Carel JC, Blumberg JSeymour C, et al. Triptorelin 3-month CPP Study Group. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty. Eur J Endocrinol 2006;154:119-24
   PubMed Web of Science ®Google Scholar
• Martínez-Aguayo A, Hernández MI, Beas F, et al. Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation. J Pediatr Endocrinol Metab 2006;19:963-70
   PubMed Web of Science ®Google Scholar
• Chiocca E, Dati E, Baroncelli GI, et al. Central precocious puberty: treatment with triptorelin 11.25 mg. ScientificWorldJournal 2012;2012:583751
   PubMedGoogle Scholar
• Bertelloni S, Cassio A, Arrigo T, et al. Central precocious puberty: short term comparative data on treatment with monthly or long-acting three months depot triptorelin. J Pediatr Endocrinol Metab 2007;20(Suppl 2):297-305
   Google Scholar
• Carel JC, Lahlou N, Jaramillo O, et al. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metab 2002;87:4111-16
   PubMed Web of Science ®Google Scholar
• Badaru A, Wilson DM, Bachrach LK, et al. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab 2006;91:1862-7
   PubMed Web of Science ®Google Scholar
• Mericq V, Lammoglia JJ, Unanue N, et al. Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: preliminary results. Clin Endocrinol 2009;71:686-90
   PubMed Web of Science ®Google Scholar
• Fuld K, Chi C, Neely EK. A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty. J Pediatr 2011;159:982-7
   PubMed Web of Science ®Google Scholar
• Lee PA, Klein K, Mauras N, et al. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J Clin Endocrinol Metab 2012;97:1572-80
   PubMedGoogle Scholar
• Isaac H, Patel L, Meyer S, et al. Efficacy of a monthly compared to 3-monthly depot GnRH analogue (goserelin) in the treatment of children with central precocious puberty. Horm Res 2007;68:157-63
   PubMedGoogle Scholar
• Trueman JA, Tillmann V, Cusick CF, et al. Suppression of puberty with long-acting goserelin (Zoladex-LA): effect on gonadotrophin response to GnRH in the first treatment cycle. Clin Endocrinol (Oxf) 2002;57:223-30
   PubMedGoogle Scholar
• Lewis KA, Eugster EA. Continual suppresion by the histrelin implant for the treatment of central precocious puberty when left in place for two years. Pediatric Academic Societies Meeting 2011;3285.1:abstract
   Google Scholar
• Gillis D, Karavani G, Hirsch HJ, et al. Time to menarche and final height after histrelin implant treatment for central precocious puberty. J Pediatr 2013; doi:pii: S0022-3476(13)00045-0
   PubMedGoogle Scholar
• Tonini G, Lazzerini M. Side effects of GnRH analogue treatment in childhood. J Pediatr Endocrinol Metab 2000;13(Suppl 1):795-803
   PubMedGoogle Scholar
• Manasco PK, Pescovitz OH, Blizzard RM. Local reactions to depot leuprolide therapy for central precocious puberty. J Pediatr 1993;123:334-5
   PubMed Web of Science ®Google Scholar
• Johnson SR, Nolan RC, Grant MT, et al. Sterile abscess formation associated with depot leuprorelin acetate therapy for central precocious puberty. J Paediatr Child Health 2012;48:E136-9
   Google Scholar
• Miller BS, Shukla AR. Sterile abscess formation in response to two separate branded long-acting gonadotropin-releasing hormone agonists. Clin Ther 2010;32:1749-51
   PubMed Web of Science ®Google Scholar
• Monroe BJ, Fallon SC, Brandt ML. Intraoperative sonographic localization of a fractured Supprelin implant in a pediatric patient: a case report. J Pediatr Endocrinol Metab 2012;25:167-9
   PubMedGoogle Scholar
• Yeshaya A, Kauschansky A, Orvieto R, et al. Prolonged vaginal bleeding during central precocious puberty therapy with a long-acting gonadotropin-releasing hormone agonist. Acta Obstet Gynecol Scand 1998;77:327-9
   PubMed Web of Science ®Google Scholar
• Heger S, Müller M, Ranke M, et al. Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function. Mol Cell Endocrinol 2006;254-255:217-20
   PubMed Web of Science ®Google Scholar
• Jay N, Mansfield MJ, Blizzard RM, et al. Ovulation and menstrual function of adolescent girls with central precocious puberty after therapy with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 1992;75:890-4
   PubMed Web of Science ®Google Scholar
• Feuillan PP, Jones JV, Barnes K, et al. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. J Clin Endocrinol Metab 1999;84:44-9
   PubMed Web of Science ®Google Scholar
• Neely EK, Lee PA, Bloch CA, et al. Leuprolide acetate 1-month depot for central precocious puberty: hormonal suppression and recovery. Int J Pediatr Endocrinol 2010;2010:398639
   PubMedGoogle Scholar
• Murram D, Dewhurst J, Grant DB. Precocious puberty: a follow up study. Arch Dis Child 1984;59:77-8
   PubMed Web of Science ®Google Scholar
• Feuillan PP, Jones JV, Barnes KM, et al. Boys with precocious puberty due to hypothalamic hamartoma: reproductive axis after discontinuation of gonadotropin-releasing hormone analog therapy. J Clin Endocrinol Metab 2000;85:4036-8
   PubMed Web of Science ®Google Scholar
• Bertelloni S, Baroncelli GI, Ferdeghini M, et al. Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues. Eur J Pediatr 2000;159:369-74
   PubMed Web of Science ®Google Scholar
• van der Sluis IM, Boot AM, Krenning EP, et al. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. J Clin Endocrinol Metab 2002;87:506-12
   PubMed Web of Science ®Google Scholar
• Antoniazzi F, Bertoldo F, Zamboni G, et al. Bone mineral metabolism in girls with precocious puberty during gonadotrophin-releasing hormone agonist treatment. Eur J Endocrinol 1995;133:412-17
   PubMed Web of Science ®Google Scholar
• Tung YC, Lee JS, Tsai WY, et al. The effects of gonadotropin releasing hormone analogue therapy on girls with gonadotropin-dependent precocious puberty. J Formos Med Assoc 2007;106:826-31
   PubMedGoogle Scholar
• Park HK, Lee HS, Ko JH, et al. The effect of gonadotrophin-releasing hormone agonist treatment over 3 years on bone mineral density and body composition in girls with central precocious puberty. Clin Endocrinol (Oxf) 2012;77:743-8
   PubMedGoogle Scholar
• Chiumello G, Brambilla P, Guarneri MP, et al. Precocious puberty and body composition: effects of GnRH analog treatment. J Pediatr Endocrinol Metab 2000;13(Suppl 1):791-4
   PubMedGoogle Scholar
• Traggiai C, Perucchin PP, Zerbini K, et al. Outcome after depot gonadotrophin-releasing hormone agonist treatment for central precocious puberty: effects on body mass index and final height. Eur J Endocrinol 2005;153:463-4
   PubMedGoogle Scholar
• Aguiar AL, Couto-Silva AC, Vicente EJ, et al. Weight evolution in girls treated for idiopathic central precocious puberty with GnRH analogues. J Pediatr Endocrinol Metab 2006;19:1327-34
   PubMed Web of Science ®Google Scholar
• Palmert M R, Mansfield M J, Crowley W. Fet al. Is obesity an outcome of gonadotropin-releasing hormone agonist administraton? Analysis of growth and body composition in 110 patients with central precocious puberty. J Clin Endocrinol Metab 1999;84:4480-7
   PubMedGoogle Scholar
• Arrigo T, De Luca F, Antoniazzi F, et al. Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty. Eur J Endocrinol 2004;150:533-7
   PubMedGoogle Scholar
• Leger J, Reynaud R, Czernichow P. Do all girls with apparent idiopathic precocious puberty require gonadotropin-releasing hormone agonist treatment? J Pediatr 2000;137:819-25
   PubMed Web of Science ®Google Scholar
• Palmert MR, Malin HV, Boepple PA. Unsustained or slowly progressive puberty in young girls: initial presentation and long-term follow-up of 20 untreated patients. J Clin Endocrinol Metab 1999;84:415-23
   PubMed Web of Science ®Google Scholar
• Lazar L, Pertzelan A, Weintrob N, et al. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height. J Clin Endocrinol Metab 2001;86:4127-32
   PubMed Web of Science ®Google Scholar
• Oostdijk W, Rikken B, Schreuder S, et al. Final height in central precocious puberty after long term treatment with a slow release GnRH agonist. Arch Dis Child 1996;75:292-7
   PubMed Web of Science ®Google Scholar
• Saggese G, Pasquino AM, Bertelloni S, et al. Effect of combined treatment with gonadotropin releasing hormone analogue and growth hormone in patients with central precocious puberty who had subnormal growth velocity and impaired height prognosis. Acta Paediatr 1995;84:299-304
   PubMed Web of Science ®Google Scholar
• Lampit M, Golander A, Guttmann H, et al. Estrogen mini-dose replacement during GnRH agonist therapy in central precocious puberty: a pilot study. J Clin Endocrinol Metab 2002;87:687-90
   PubMedGoogle Scholar
• Pucarelli I, Segni M, Ortore M, et al. Effects of combined gonadotropin-releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: a further contribution. J Pediatr Endocrinol Metab 2003;16:1005-10
   PubMed Web of Science ®Google Scholar
• Michaud PA, Suris JC, Deppen A. Gender-related psychological and behavioural correlates of pubertal timing in a national sample of Swiss adolescents. Mol Cell Endocrinol 2006;254-255:172-8
   PubMed Web of Science ®Google Scholar
• Copeland W, Shanahan L, Miller S, et al. Outcomes of early pubertal timing in young women: a prospective population-based study. Am J Psychiatry 2010;167:1218-25
   PubMed Web of Science ®Google Scholar
• Johansson T, Ritzen EM. Very long-term follow-up of girls with early and late menarche. Endocr Dev 2005;8:126-36
   PubMedGoogle Scholar
• Gluckman PD, Hanson MA. Evolution, development and timing of puberty. Trends Endocrinol Metab 2006;17:7-12
   PubMed Web of Science ®Google Scholar
• Mul D, Versluis-den Bieman HJ, Slijper FM, et al. Psychological assessments before and after treatment of early puberty in adopted children. Acta Paediatr 2001;90:965-71
   PubMedGoogle Scholar
• Xhrouet-Heinrichs D, Lagrou K, Heinrichs C, et al. Longitudinal study of behavioral and affective patterns in girls with central precocious puberty during long-acting triptorelin therapy. Acta Paediatr 1997;86:808-15
   PubMedGoogle Scholar
• Kim EY, Lee MI. Psychosocial aspects in girls with idiopathic precocious puberty. Psychiatry Invest 2012;9:25-8
   PubMed Web of Science ®Google Scholar
• Officio A, Griso G, Frascogna AR, et al. Adulthood issues in idiopathic central precocious puberty. J Pediatr Endocrinol Metab 2007;20(Suppl 2):325-9
   Google Scholar